Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

Horizon Technology Finance

Valor Equity Partners

Paragon Biosciences

Fidelity Management and Research Company

Bain Capital Life Sciences

Emalex Biosciences

We are conducting a Phase 3 clinical trial for a potential therapeutic to treat Tourette syndrome. The study evaluates a therapeutic in children, adolescents and adults. Sites are in North America and Europe. Study details are available here: https://lnkd.in/gm_Sxfvy

#tourettesyndrome #clinicaltrial 

Remembering Dr. Martin Luther King, Jr. today. His commitment to combating injustice and fostering inclusivity continues to inspire. #martinlutherkingjr 

Focused on developing novel therapies for rare endocrine disorders

Spruce Biosciences Inc

Specializes in oral drug delivery for rare and serious chronic diseases

Chiasma Inc

Develops novel medications for central nervous system disorders and pain management

Vallon Pharmaceuticals Inc

Provides education and training in biotechnology and life sciences

Biotech Primer Inc

Emalex Biosciences is a biopharmaceutical company dedicated to developing new treatments for rare and orphan neurological conditions. Their first development candidate, Ecopipam, is a novel compound studied as a potential treatment for central nervous system (CNS) disorders, including pediatric Tourette Syndrome.

Emalex Biosciences, LLC

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 4, 2024 3:02 PM	5c03d24a
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 4, 2024 3:02 PM	7ddc2a1e
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	9c6bb41a
crunchbase profile	general
li profile	general	Mar 4, 2024 3:02 PM	16eac035
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 4, 2024 3:02 PM	424f56c5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:EMALEXBIOSCIENCES

Emalex Biosciences, LLC